1. Chordia Therapeutics Inc.
  2. News
News
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • 現在位置:News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

News

  • Jul 14, 2025 Non-consolidated Financial Results for the Nine Months Ended May 31, 2025 [Japanese GAAP] pdf （440KB）
  • Jul 08, 2025 Notice of Commencement of Joint Research with D. Western Therapeutics Institute, Inc. pdf （231KB）
  • Jun 19, 2025 Notice of Receipt of Grant pdf （281KB）
  • May 15, 2025 Notice Concerning Change of Major Shareholder pdf （249KB）
  • Apr 28, 2025 Notice of Discontinuation of Development of CTX-177 (ONO-7018) pdf （289KB）
  • Apr 25, 2025 Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025 pdf （229KB）
  • Apr 24, 2025 Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2025 pdf （276KB）
  • Apr 11, 2025 For 2nd quarter FY8 2025 Financial Results Presentation pdf （1,132KB）
  • Apr 11, 2025 Non-consolidated Financial Results for the Six Months Ended February 28, 2025 [Japanese GAAP] pdf （442KB）
  • Apr 01, 2025 Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2025 pdf （233KB）
  • Jan 14, 2025 Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP] pdf （432KB）
  • Jan 10, 2025 Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA pdf （272KB）
  • Dec 12, 2024 By FISCO Corporation Notice of Distribution of Our Corporate Research Report pdf （267KB）
  • Nov 29, 2024 Corporate Governance Report pdf （659KB）
  • Nov 20, 2024 Announcement of International Nonproprietary Name (INN) for CTX-712 pdf （277KB）
  • Nov 06, 2024 Notice of Convocation of the 7th Annual General Meeting of Shareholders pdf （942KB）
  • Oct 28, 2024 Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2024 pdf （281KB）
  • Oct 15, 2024 Fiscal year ended August 2024 Financial Results Presentation pdf （1,465KB）
  • Oct 11, 2024 Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2024 [Japanese GAAP] pdf （538KB）
  • Oct 11, 2024 Chordia to Present Results of Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2024 The 86th Annual Meeting of the Japanese Society of Hematolog pdf （283KB）
  • Oct 02, 2024 Chordia was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2024 pdf （405KB）
  • Oct 01, 2024 Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology pdf （281KB）
  • Jul 23, 2024 Chordia wins the Minister of Education, Culture, Sports, Science and Technology Award at the Japan Startup Awards 2024. pdf （610KB）
  • Jul 16, 2024 Non-consolidated Financial Results for the Nine Months Ended May 31, 2024 [Japanese GAAP] pdf （348KB）
  • Jun 14, 2024 Notice of Listing on the Growth Market of the Tokyo Stock Exchange pdf （522KB）
  • Jun 07, 2024 CSO Daisuke Morishita to Speak at the 28th Annua Meeting of Japanese Association for Molecular Target Therapy of Cancer pdf （280KB）
  • Apr 17, 2024 Joint presentation about CDK12 at the 76th Annual Meeting of the Japanese Society of Obstetrics and Gynecology pdf （289KB）
  • Apr 06, 2024 Chordia Presented at the American Association for Cancer Research Annual Meeting 2024 pdf （304KB）
  • Mar 14, 2024 Presentation at 3rd regional symposium on Myelodysplastic syndrome pdf （261KB）
  • Mar 06, 2024 Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2024 pdf （300KB）
  • Feb 15, 2024 CSO Daisuke Morishita receives the Minister of State for Science and Technology Policy Award at the 6th Japan Open Innovation Prize
  • Feb 14, 2024 Chordia CEO to Speak at the Japan Healthcare Venture Summit 2023 Symposium pdf （269KB）
  • Jan 29, 2024 Chordia nominated for the 6th Japan Open Innovation Prize pdf （266KB）
  • Nov 28, 2023 Published 6th Financial Report pdf （300KB）
  • Nov 20, 2023 Chordia Announces Completion of Patient Enrollment in the Phase 1 Study for Solid Tumors and Hematologic Malignancies in Japan pdf （385KB）
  • Oct 19, 2023 Chordia named "Financing Deal of the Year." at the Informa Pharma Intelligence Awards Japan 2023 pdf （355KB）
  • Oct 18, 2023 Chordia named “Judges' Special Award” at Japan Healthcare Venture Summit 2023 pdf （269KB）
  • Oct 18, 2023 Abstract of the summary presentation of the US Phase 1/2 clinical trial of CTX-712 has been accepted at the 65th ASH pdf （293KB）
  • Oct 01, 2023 Yasushi Tanoue appointed Chief Medical Officer (CMO) pdf （274KB）
  • Sep 15, 2023 Selected for the latest edition of "100 Amazing Venture Businesses" in 2023 pdf （184KB）
  • Sep 15, 2023 Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2023 pdf （267KB）
  • Jun 01, 2023 Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf （299KB）
  • May 17, 2023 Fujitsu, Kyoto University, and Chordia Therapeutics Launch AI Trials to Discover Biomarkers for New Cancer Drugs pdf （147KB）
  • Feb 17, 2023 Initiated Phase 1/2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf （301KB）
  • Feb 16, 2023 Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor, According to License Agreement with Ono Pharmaceutical pdf （238KB）
  • Dec 12, 2022 Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting. pdf （284KB）
  • Nov 21, 2022 Published 5th Financial Report pdf （496KB）
  • Oct 03, 2022 Chordia Therapeutics Director and Statutory Auditor Appointments pdf （263KB）
  • Sep 08, 2022 Chordia Named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022 pdf （270KB）
  • Aug 29, 2022 Chordia’s Licensee Ono Pharmaceutical Co., Ltd. Initiated a Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S. pdf （281KB）
  • Jun 07, 2022 Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting pdf （304KB）
  • Jun 07, 2022 Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd. pdf （216KB）
  • May 19, 2022 Concludes Basic Agreement on Business Tie Up with MEDIPAL HOLDINGS CORPORATION pdf （232KB）
  • May 19, 2022 Raises Approximately 4 Billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 Billion JPY pdf （215KB）
  • May 16, 2022 Featured as a Cover Story in Startup City Magazine’s “Top 10 Japanese Startups 2022” pdf （2,325KB）
  • Apr 07, 2022 Nominated as a Finalist of the Informa Pharma Intelligence Awards Japan 2022 pdf （302KB）
  • Dec 03, 2021 Published 4th financial report pdf （660KB）
  • Sep 24, 2021 Assignment of Statutory Auditor pdf （92KB）
  • Mar 03, 2021 Interview with CEO Miyake Published in Scrip
  • Feb 04, 2021 Interview with CSO Morishita Published in AnswersNews
  • Dec 15, 2020 Notice of License Agreement pdf （121KB）
  • Oct 25, 2019 Chordia Therapeutics Announced the Appointment of CMO & CSO pdf （181KB）
  • Mar 29, 2019 Chordia Therapeutics Raises Around $27 Million in Series B Financing pdf （212KB）
  • Jan 10, 2019 Published Our Article in Forbes JAPAN
  • Nov 30, 2017 Chordia Therapeutics Raises Around $11 Million in Series A Financing pdf （562KB）
  • Nov 22, 2017 Launch of Chordia Therapeutics pdf （562KB）

VIEW ALL

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box